3,4-dihydroxyphenylacetic acid has been researched along with Dyskinesia, Medication-Induced in 25 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa (l-DOPA, l-3,4-dihydroxyphenylalanine) is the most effective drug in the symptomatic treatment of Parkinson's disease (PD), but chronic use initiates a maladaptive process leading to l-DOPA-induced dyskinesia (LID)." | 1.46 | Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H, 2017) |
| " Chronic administration of ceruletide (160 micrograms." | 1.29 | Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNAs in the striatum of rats with dyskinesia induced by iminodipropionitrile. ( Asanuma, M; Hirata, H; Mori, A; Ogawa, N; Ota, Z, 1993) |
| "Pergolide mesylate is a potent dopamine agonist that is being evaluated clinically in Parkinson disease, hyperprolactinemia, and other diseases." | 1.26 | Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia. ( Clemens, JA; Fuller, RW; Hynes, MD, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (36.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morin, N | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Di Paolo, T | 2 |
| Andersen, AD | 1 |
| Blaabjerg, M | 1 |
| Binzer, M | 1 |
| Kamal, A | 1 |
| Thagesen, H | 1 |
| Kjaer, TW | 1 |
| Stenager, E | 1 |
| Gramsbergen, JBP | 1 |
| Dupre, KB | 2 |
| Eskow, KL | 2 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Negron, GE | 1 |
| Lormand, L | 1 |
| Park, JY | 2 |
| Bishop, C | 3 |
| Barnum, CJ | 1 |
| Dickinson, SO | 1 |
| Yabe, H | 1 |
| Choudhury, ME | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
| Taylor, JL | 1 |
| Walker, PD | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Kolbe, H | 1 |
| Clow, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Jeste, DV | 2 |
| Doongaji, DR | 1 |
| Linnoila, M | 1 |
| Fuller, RW | 1 |
| Clemens, JA | 1 |
| Hynes, MD | 1 |
| See, RE | 1 |
| Hirata, H | 1 |
| Ogawa, N | 2 |
| Asanuma, M | 2 |
| Ota, Z | 1 |
| Mori, A | 1 |
| Iida, K | 1 |
| Iwata, E | 1 |
| Asanuma, SN | 1 |
| Gómez-Vargas, M | 1 |
| Miyazaki, I | 1 |
| Nakanishi, T | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Lohr, JB | 1 |
| Kuczenski, R | 1 |
| Bracha, HS | 1 |
| Moir, M | 1 |
| Johansson, PE | 1 |
| Terenius, L | 1 |
| Häggström, JE | 1 |
| Gunne, L | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| Drumheller, A | 1 |
| Frecska, E | 1 |
| Bagdy, G | 1 |
| Perenyi, A | 1 |
| Arato, M | 1 |
| Degrell, I | 1 |
| Mogyorosy, Z | 1 |
| Stahl, SM | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owen, F | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Corsini, GU | 1 |
| Pintus, S | 1 |
| Chiueh, CC | 1 |
| Weiss, JF | 1 |
| Kopin, IJ | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Bédard, PJ | 1 |
| Boucher, R | 1 |
| Kozell, L | 1 |
| Sandyk, R | 1 |
| Wagner, GC | 1 |
| Fisher, H | 1 |
25 other studies available for 3,4-dihydroxyphenylacetic acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; | 2017 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Di | 2008 |
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Hydrox | 2009 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsan | 2009 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Erythrocyt | 1981 |
Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Homovan | 1984 |
Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corticosterone; Dopamine; Dose-Response Relationship | 1982 |
Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-In | 1993 |
Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNAs in the striatum of rats with dyskinesia induced by iminodipropionitrile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzazepines; Blotting, Northern; Ceruletide; Corpus Striat | 1993 |
Effects of repeated cyclosporin A administration on iminodipropionitrile-induced dyskinesia and TRE-/CRE-binding activities in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cell Nucleus; Corpus Striatum; Cyclic AMP; Cyclospor | 1998 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; | 1990 |
Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Cebus; Corpus Striatum; | 1990 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Brain; Dopamine; Dopamine beta-Hydroxylase; Dyskinesia, | 1989 |
CSF monamine metabolites in movement disorders and normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho | 1985 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Halope | 1987 |